3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Genomma Lab InternacionalB de CV's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 52.18%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
MEX:LABB's 3-Year ROIIC % is ranked better than 84% of 944
companies
in the Drug Manufacturers industry
Industry Median: 3.815
vs MEX:LABB: 52.18
Genomma Lab InternacionalB de CV (MEX:LABB) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Genomma Lab InternacionalB de CV 3-Year ROIIC % Related Terms
Genomma Lab InternacionalB de CV 3-Year ROIIC % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genomma Lab InternacionalB de CV 3-Year ROIIC % Chart
MEX:LABB vs ZTS, UTHR, VTRS: 3-Year ROIIC % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Genomma Lab InternacionalB de CV's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genomma Lab InternacionalB de CV 3-Year ROIIC % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Genomma Lab InternacionalB de CV's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Genomma Lab InternacionalB de CV's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Genomma Lab InternacionalB de CV (MEX:LABB) has a 3-Year ROIIC % of 52.18 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Genomma Lab InternacionalB de CV and its competitors. This is 188% above median its historical median of 18.12. According to the industry distribution chart, Genomma Lab InternacionalB de CV ranks #151 out of 944 companies in the Drug Manufacturers industry, placing it in the top 16%.
Is Genomma Lab InternacionalB de CV's 3-Year ROIIC % too high?
Genomma Lab InternacionalB de CV's current 3-Year ROIIC % of 52.18 is 188% above median its 10-year median of 18.12. The Drug Manufacturers industry median 3-Year ROIIC % is 3.82. Genomma Lab InternacionalB de CV's value of 52.18 is 1267.8% above this industry median. Based on the distribution chart, Genomma Lab InternacionalB de CV ranks #151 out of 944 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Genomma Lab InternacionalB de CV has a GF Score™ of 66/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genomma Lab InternacionalB de CV's 3-Year ROIIC % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Genomma Lab InternacionalB de CV ranks #151 out of 944 companies for 3-Year ROIIC %. This places Genomma Lab InternacionalB de CV in the top 16% of its industry — outperforming the majority of peers. The industry median 3-Year ROIIC % is 3.82. Genomma Lab InternacionalB de CV's value of 52.18 is 1267.8% above this benchmark. While the company's 10-year median is 18.12 vs. the industry median of 3.82, Genomma Lab InternacionalB de CV has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Drug Manufacturers company?
The median 3-Year ROIIC % among Drug Manufacturers companies is 3.82, based on 944 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genomma Lab InternacionalB de CV's current 3-Year ROIIC % of 52.18 is 1267.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Genomma Lab InternacionalB de CV and its competitors. For the Drug Manufacturers industry, the median 3-Year ROIIC % is 3.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genomma Lab InternacionalB de CV's current 3-Year ROIIC % is 52.18, which is 188% above median its own 10-year median of 18.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genomma Lab InternacionalB de CV stock overvalued right now?
Based on GuruFocus' analysis, Genomma Lab InternacionalB de CV (MEX:LABB) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN17.64, compared to a current price of MXN14.97 — trading 15.1% below its estimated fair value. The current 3-Year ROIIC % is 52.18, which is 188% above median its 10-year median of 18.12 and 1267.8% above the Drug Manufacturers industry median of 3.82. Genomma Lab InternacionalB de CV's overall GF Score™ is 66/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Genomma Lab InternacionalB de CV (MEX:LABB), the current 3-Year ROIIC % is 52.18 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genomma Lab InternacionalB de CV (MEX:LABB) Overvalued in 2026?
Based on GuruFocus' analysis, Genomma Lab InternacionalB de CV stock appears to be undervalued.
The current stock price of MXN14.97 is trading 15.1% below its estimated GF Value™ of MXN17.64.
GuruFocus considers Genomma Lab InternacionalB de CV to be Modestly Undervalued.
Key valuation signals for MEX:LABB:
3-Year ROIIC %: 52.18 (188% above median its 10-year median of 18.12)
GF Value™: MXN17.64 vs. price of MXN14.97 (15.1% below fair value)
Industry Position: 1267.8% above the Drug Manufacturers median (#151 of 944)
No single metric tells the full story. See the MEX:LABB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genomma Lab InternacionalB de CV Business Description
Genomma Lab Internacional SAB de CV is a specialty and generic drug manufacturer. The company's stated goal is to improve and preserve the health and well-being of people through innovative, safe, and effective products. Genomma operates a wide variety of brands to serve different consumer needs, including pregnancy, pain medication, and deodorant. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
66GF Score
Get the complete analysis for MEX:LABB
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:LABB has been successfully added to your 
